Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OneMedForum Finance Conference 2010
http://www.onemedplace.com/onemedforum/
Held annually in San Francisco, the OneMedPlace Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners. Over 100 company presentations will occur by some of the most promising - and typically least recognized - companies in the world. Recognizing the impacts and opportunities connected to healthcare reform and the stimulus package, we have added a third day dedicated to Health Information. Join us at The Sir Francis Drake Hotel, as it will be the destination for those who are interested in emerging healthcare and life sciences companies.
PRESENTING COMPANIES : http://www.onemedplace.com/onemedforum/companies.php
OneMedForum Finance Conference 2010
http://www.onemedplace.com/onemedforum/
Held annually in San Francisco, the OneMedPlace Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners. Over 100 company presentations will occur by some of the most promising - and typically least recognized - companies in the world. Recognizing the impacts and opportunities connected to healthcare reform and the stimulus package, we have added a third day dedicated to Health Information. Join us at The Sir Francis Drake Hotel, as it will be the destination for those who are interested in emerging healthcare and life sciences companies.
PRESENTING COMPANIES : http://www.onemedplace.com/onemedforum/companies.php
Upcoming Events (3) Triglycerides and Triglyceride (January 9_-_14,_2010)
http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=1033
Triglycerides and Triglyceride-Rich Particles in Health and Disease (A3)
Supported by The Directors' Fund
Organizers: Robert H. Eckel, Ira J. Goldberg and Ruth McPherson
January 9 - 14, 2010 • Big Sky Resort • Big Sky, Montana
Upcoming Events (2) Structural Genomics (January 8_-_13,_2010)
http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=1026
Structural Genomics: Expanding the Horizons of Structural Biology (J2)
Supported by The Directors' Fund
Organizers: Ian A. Wilson, Kurt Wüthrich, Soichi Wakatsuki and Christine A. Orengo
January 8 - 13, 2010 • Beaver Run Resort • Breckenridge, Colorado
Upcoming Events (1) Advances in Biopharmaceuticals (January_8_-_13,_2010)
http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=1029
Advances in Biopharmaceuticals (A2)
Sponsored by Alnylam Pharmaceuticals, Inc. and Pfizer Global Research & Development
Organizers: John M. McPherson and Thomas F. Bumol
January 8 - 13, 2010 • Zermatt Resort & Spa - Utah • Midway, Utah
KERX -
Keryx Biopharmaceuticals to Present at the J.P. Morgan 28th Annual Healthcare Conference
Date : 01/07/2010 @ 11:52AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)
http://ih.advfn.com/p.php?pid=nmona&cb=1262985783&article=41012769&symbol=N^KERX
NexMed Provides Corporate Update
Date : 01/08/2010 @ 12:00PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
http://ih.advfn.com/p.php?pid=nmona&cb=1262970500&article=41031116&symbol=N^NEXM
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, today provided an update on ongoing corporate activities and the status of the Company’s NASDAQ listing
Product Pipeline Topical Alprostadil Treatments NexMed expects to hear from Health Canada concerning the approvability of its New Drug Submission (NDS) for Vitaros®, its topical treatment for erectile dysfunction, sometime in February 2010. As such, management has postponed negotiations with its potential partner until an approval decision from Health Canada is received, as partnering negotiations with a marketing approval would be expected to yield more favorable terms for the Company
In the U.S., NexMed is awaiting a response from the Food and Drug Administration (FDA) regarding the carcinogenicity (CAC) assessment package, which it expects to occur within the next two months. Partnering efforts for Femprox®, NexMed’s topical treatment for female sexual dysfunction, are on hold pending the final decision by the FDA
Outside of North America, NexMed is awaiting Health Canada or the FDA’s response to accelerate partnering efforts and/or filing for marketing approvals. To date, NexMed has received multiple indications of interest from international pharmaceutical companies that might be interested in partnering with NexMed
In addition, through its Bio-Quant research and development team, NexMed is running new efficacy studies on the Vitaros formulation to assess the potential of the compound for other indications such as wound healing and Raynaud’s Syndrome. NexMed’s strategy is to take advantage of the development work already completed for Vitaros and bolster the existing database with new data and apply it to potentially shorten the path of approval. The goal includes commencing partnering discussions in mid-2010 for the new indications, if the pre-clinical data are positive
NM100060 Onychomycosis Treatment NexMed is actively engaged in efforts to re-license this product for the treatment of nail fungus. In the meantime, Novartis continues to transfer the clinical and regulatory dossiers to the Company and the data are being shared with potential partners
Topical Psoriasis Treatment NexMed’s Bio-Quant R&D team is also proceeding with extensive pre-clinical efficacy studies to strengthen its psoriasis candidate while actively engaging in partnering discussions
Topical NSAID Program NexMed is also exploring the opportunity to license an early stage NSAID program, which includes an issued U.S. patent. This program was not pursued when NexMed chose to focus its resources on its sexual dysfunction programs. Preclinical data of the NexACT-based ketoprofen cream has shown more rapid and efficient delivery of the drug as compared to the currently marketed products
NexACT technology, Partnering as a Service NexMed has initiated discussions with potential partners regarding the application of its NexACT technology to drugs that will soon be going off-patent to help create a second-generation drug that has patent protection through the mechanism of delivery. The NexACT platform technology has demonstrated the potential to improve the topical absorption of active therapeutic ingredients and/or to develop new patient-friendlier routes of administration. Incorporating older drugs with the NexACT proprietary delivery system can create new products that not only provide patients with added therapeutic benefits, but can also extend the product life for up to an additional 20 years. As such, the Company intends to aggressively pursue these types of potential partnering arrangements going forward
NexACT technology, New Applications In addition to developing innovative topical treatments, NexMed’s new scientific team is evaluating the ability of the NexACT technology to deliver biologics, such as humanized or fully human antibodies, via transdermal application. The delivery of such biologics through the skin represents a novel approach to delivering antibodies to specific areas of the body with limited systemic exposure – potentially reducing side effects and toxicity. We are also evaluating the ability of the NexACT technology to deliver drugs orally, including various first-line oral chemotherapeutics, which currently have poor bioavailability and thus require high doses and result in certain toxic side effects
NASDAQ Listing On January 4, 2010, NexMed received an expected notice of non-compliance from The NASDAQ Stock Market LLC based upon its failure to solicit proxies and hold an annual meeting for fiscal 2008 by December 31, 2009, as required by NASDAQ Listing Rules 5620(a) and 5620(b), which could serve as an additional basis for the delisting of the Company’s securities from The NASDAQ Capital Market. NexMed had discussed this matter with the NASDAQ Listing Qualifications Panel (the “Panel”) at the hearing on November 12, 2009, and explained that it planned to postpone the 2008 annual meeting due to the ongoing acquisition of Bio-Quant and would not be able to incorporate all of the relevant acquisition related materials in the meeting proxy in a timely manner
As NexMed previously announced on December 18, 2009, the Panel granted its request to remain listed on The NASDAQ Capital Market, subject to the condition that it evidence stockholders’ equity of at least $2.5 million or a market value of listed securities of at least $35 million on or before March 31, 2010. The determination followed the hearing before the Panel on November 12, 2009, at which time NexMed presented its plan to evidence compliance with all requirements for continued listing on The NASDAQ Capital Market, including the proxy solicitation/annual meeting and bid price requirements (notwithstanding the fact that NexMed was not yet deficient with respect to those standards)
As provided by NASDAQ’s most recent notice, NexMed plans to timely make a formal written submission to the Panel presenting its plan to evidence compliance with the proxy solicitation and annual meeting requirements. While it intends to file a proxy statement for a special meeting of shareholders to be held within the next sixty days to consider amending its Articles of Incorporation to authorize more common stock for issuance, that meeting may not be conducted as an annual meeting since the proxy statement will not incorporate audited financial statements for the fiscal year ended December 31, 2009. As a result, in order to satisfy NASDAQ’s annual meeting requirement, NexMed plans to file a proxy statement for a joint 2008/2009 annual meeting promptly following the filing of its Annual Report on Form 10-K for fiscal 2009 in March 2010. Accordingly, the Company is asking the Panel to modify its previously issued decision in accordance with the Company’s revised plan of compliance. However, there can be no assurance that the Panel will grant the Company’s request
Also as previously announced, NexMed remains subject to a grace period through January 25, 2010 to evidence compliance with the $1.00 bid price requirement for continued listing on NASDAQ. In the event NexMed does not evidence compliance with the bid price requirement by that date, NexMed expects to receive an additional formal notice of non-compliance and to be afforded an opportunity to request an exception from the Panel to evidence compliance with the minimum bid price requirement. In that regard, NexMed will implement a reverse stock split, if necessary, to evidence compliance with NASDAQ’s minimum bid price requirement, which action may be taken at any time at the discretion of the NexMed Board of Directors
Corporate Integration Subsequent to the December 17, 2009 announcement of the lease of its manufacturing building in New Jersey, NexMed has completed the relocation of its headquarters to 6330 Nancy Ridge Drive, San Diego, CA 92121. NexMed now has 34 full time employees, of whom eight employees hold either Ph.D or MD degrees. NexMed will include the pro forma financial statements for the combined entity in an amendment to its December 17, 2009 Current Report on Form 8-K, to be filed on or before February 26, 2010
About NexMed NexMed, due to its recent acquisition of Bio-Quant, is the largest specialty contract research organization (“CRO”) based in San Diego, CA and is one of the industry’s most experienced CROs for in vitro and in vivo pharmacology services and research models. NexMed has a proprietary product pipeline based on its NexACT drug delivery technology, including a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information, go to www.nexmed.com and www.bio-quant.com
Forward-Looking Statement Safe Harbor Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company. For example, and without limitation, there can be no assurance that the Company will receive favorable approvability decisions from Health Canada or the FDA within the anticipated time frames or at all, the Company’s research and development activities will yield the desired results, the Company will be able to achieve or will continue to pursue its product development goals, the Company will be able to execute on its partnering strategies, the Company will be able to satisfy NASDAQ continued listing standards, and that the Company will be able to integrate its business following the Bio-Quant acquisition in a successful manner
NexMed Provides Corporate Update
Date : 01/08/2010 @ 12:00PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
http://ih.advfn.com/p.php?pid=nmona&cb=1262970500&article=41031116&symbol=N^NEXM
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, today provided an update on ongoing corporate activities and the status of the Company’s NASDAQ listing
Product Pipeline Topical Alprostadil Treatments NexMed expects to hear from Health Canada concerning the approvability of its New Drug Submission (NDS) for Vitaros®, its topical treatment for erectile dysfunction, sometime in February 2010. As such, management has postponed negotiations with its potential partner until an approval decision from Health Canada is received, as partnering negotiations with a marketing approval would be expected to yield more favorable terms for the Company
In the U.S., NexMed is awaiting a response from the Food and Drug Administration (FDA) regarding the carcinogenicity (CAC) assessment package, which it expects to occur within the next two months. Partnering efforts for Femprox®, NexMed’s topical treatment for female sexual dysfunction, are on hold pending the final decision by the FDA
Outside of North America, NexMed is awaiting Health Canada or the FDA’s response to accelerate partnering efforts and/or filing for marketing approvals. To date, NexMed has received multiple indications of interest from international pharmaceutical companies that might be interested in partnering with NexMed
In addition, through its Bio-Quant research and development team, NexMed is running new efficacy studies on the Vitaros formulation to assess the potential of the compound for other indications such as wound healing and Raynaud’s Syndrome. NexMed’s strategy is to take advantage of the development work already completed for Vitaros and bolster the existing database with new data and apply it to potentially shorten the path of approval. The goal includes commencing partnering discussions in mid-2010 for the new indications, if the pre-clinical data are positive
NM100060 Onychomycosis Treatment NexMed is actively engaged in efforts to re-license this product for the treatment of nail fungus. In the meantime, Novartis continues to transfer the clinical and regulatory dossiers to the Company and the data are being shared with potential partners
Topical Psoriasis Treatment NexMed’s Bio-Quant R&D team is also proceeding with extensive pre-clinical efficacy studies to strengthen its psoriasis candidate while actively engaging in partnering discussions
Topical NSAID Program NexMed is also exploring the opportunity to license an early stage NSAID program, which includes an issued U.S. patent. This program was not pursued when NexMed chose to focus its resources on its sexual dysfunction programs. Preclinical data of the NexACT-based ketoprofen cream has shown more rapid and efficient delivery of the drug as compared to the currently marketed products
NexACT technology, Partnering as a Service NexMed has initiated discussions with potential partners regarding the application of its NexACT technology to drugs that will soon be going off-patent to help create a second-generation drug that has patent protection through the mechanism of delivery. The NexACT platform technology has demonstrated the potential to improve the topical absorption of active therapeutic ingredients and/or to develop new patient-friendlier routes of administration. Incorporating older drugs with the NexACT proprietary delivery system can create new products that not only provide patients with added therapeutic benefits, but can also extend the product life for up to an additional 20 years. As such, the Company intends to aggressively pursue these types of potential partnering arrangements going forward
NexACT technology, New Applications In addition to developing innovative topical treatments, NexMed’s new scientific team is evaluating the ability of the NexACT technology to deliver biologics, such as humanized or fully human antibodies, via transdermal application. The delivery of such biologics through the skin represents a novel approach to delivering antibodies to specific areas of the body with limited systemic exposure – potentially reducing side effects and toxicity. We are also evaluating the ability of the NexACT technology to deliver drugs orally, including various first-line oral chemotherapeutics, which currently have poor bioavailability and thus require high doses and result in certain toxic side effects
NASDAQ Listing On January 4, 2010, NexMed received an expected notice of non-compliance from The NASDAQ Stock Market LLC based upon its failure to solicit proxies and hold an annual meeting for fiscal 2008 by December 31, 2009, as required by NASDAQ Listing Rules 5620(a) and 5620(b), which could serve as an additional basis for the delisting of the Company’s securities from The NASDAQ Capital Market. NexMed had discussed this matter with the NASDAQ Listing Qualifications Panel (the “Panel”) at the hearing on November 12, 2009, and explained that it planned to postpone the 2008 annual meeting due to the ongoing acquisition of Bio-Quant and would not be able to incorporate all of the relevant acquisition related materials in the meeting proxy in a timely manner
As NexMed previously announced on December 18, 2009, the Panel granted its request to remain listed on The NASDAQ Capital Market, subject to the condition that it evidence stockholders’ equity of at least $2.5 million or a market value of listed securities of at least $35 million on or before March 31, 2010. The determination followed the hearing before the Panel on November 12, 2009, at which time NexMed presented its plan to evidence compliance with all requirements for continued listing on The NASDAQ Capital Market, including the proxy solicitation/annual meeting and bid price requirements (notwithstanding the fact that NexMed was not yet deficient with respect to those standards)
As provided by NASDAQ’s most recent notice, NexMed plans to timely make a formal written submission to the Panel presenting its plan to evidence compliance with the proxy solicitation and annual meeting requirements. While it intends to file a proxy statement for a special meeting of shareholders to be held within the next sixty days to consider amending its Articles of Incorporation to authorize more common stock for issuance, that meeting may not be conducted as an annual meeting since the proxy statement will not incorporate audited financial statements for the fiscal year ended December 31, 2009. As a result, in order to satisfy NASDAQ’s annual meeting requirement, NexMed plans to file a proxy statement for a joint 2008/2009 annual meeting promptly following the filing of its Annual Report on Form 10-K for fiscal 2009 in March 2010. Accordingly, the Company is asking the Panel to modify its previously issued decision in accordance with the Company’s revised plan of compliance. However, there can be no assurance that the Panel will grant the Company’s request
Also as previously announced, NexMed remains subject to a grace period through January 25, 2010 to evidence compliance with the $1.00 bid price requirement for continued listing on NASDAQ. In the event NexMed does not evidence compliance with the bid price requirement by that date, NexMed expects to receive an additional formal notice of non-compliance and to be afforded an opportunity to request an exception from the Panel to evidence compliance with the minimum bid price requirement. In that regard, NexMed will implement a reverse stock split, if necessary, to evidence compliance with NASDAQ’s minimum bid price requirement, which action may be taken at any time at the discretion of the NexMed Board of Directors
Corporate Integration Subsequent to the December 17, 2009 announcement of the lease of its manufacturing building in New Jersey, NexMed has completed the relocation of its headquarters to 6330 Nancy Ridge Drive, San Diego, CA 92121. NexMed now has 34 full time employees, of whom eight employees hold either Ph.D or MD degrees. NexMed will include the pro forma financial statements for the combined entity in an amendment to its December 17, 2009 Current Report on Form 8-K, to be filed on or before February 26, 2010
About NexMed NexMed, due to its recent acquisition of Bio-Quant, is the largest specialty contract research organization (“CRO”) based in San Diego, CA and is one of the industry’s most experienced CROs for in vitro and in vivo pharmacology services and research models. NexMed has a proprietary product pipeline based on its NexACT drug delivery technology, including a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information, go to www.nexmed.com and www.bio-quant.com
Forward-Looking Statement Safe Harbor Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company. For example, and without limitation, there can be no assurance that the Company will receive favorable approvability decisions from Health Canada or the FDA within the anticipated time frames or at all, the Company’s research and development activities will yield the desired results, the Company will be able to achieve or will continue to pursue its product development goals, the Company will be able to execute on its partnering strategies, the Company will be able to satisfy NASDAQ continued listing standards, and that the Company will be able to integrate its business following the Bio-Quant acquisition in a successful manner
NexMed Provides Corporate Update
Date : 01/08/2010 @ 12:00PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
http://ih.advfn.com/p.php?pid=nmona&cb=1262970500&article=41031116&symbol=N^NEXM
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, today provided an update on ongoing corporate activities and the status of the Company’s NASDAQ listing
Product Pipeline Topical Alprostadil Treatments NexMed expects to hear from Health Canada concerning the approvability of its New Drug Submission (NDS) for Vitaros®, its topical treatment for erectile dysfunction, sometime in February 2010. As such, management has postponed negotiations with its potential partner until an approval decision from Health Canada is received, as partnering negotiations with a marketing approval would be expected to yield more favorable terms for the Company
In the U.S., NexMed is awaiting a response from the Food and Drug Administration (FDA) regarding the carcinogenicity (CAC) assessment package, which it expects to occur within the next two months. Partnering efforts for Femprox®, NexMed’s topical treatment for female sexual dysfunction, are on hold pending the final decision by the FDA
Outside of North America, NexMed is awaiting Health Canada or the FDA’s response to accelerate partnering efforts and/or filing for marketing approvals. To date, NexMed has received multiple indications of interest from international pharmaceutical companies that might be interested in partnering with NexMed
In addition, through its Bio-Quant research and development team, NexMed is running new efficacy studies on the Vitaros formulation to assess the potential of the compound for other indications such as wound healing and Raynaud’s Syndrome. NexMed’s strategy is to take advantage of the development work already completed for Vitaros and bolster the existing database with new data and apply it to potentially shorten the path of approval. The goal includes commencing partnering discussions in mid-2010 for the new indications, if the pre-clinical data are positive
NM100060 Onychomycosis Treatment NexMed is actively engaged in efforts to re-license this product for the treatment of nail fungus. In the meantime, Novartis continues to transfer the clinical and regulatory dossiers to the Company and the data are being shared with potential partners
Topical Psoriasis Treatment NexMed’s Bio-Quant R&D team is also proceeding with extensive pre-clinical efficacy studies to strengthen its psoriasis candidate while actively engaging in partnering discussions
Topical NSAID Program NexMed is also exploring the opportunity to license an early stage NSAID program, which includes an issued U.S. patent. This program was not pursued when NexMed chose to focus its resources on its sexual dysfunction programs. Preclinical data of the NexACT-based ketoprofen cream has shown more rapid and efficient delivery of the drug as compared to the currently marketed products
NexACT technology, Partnering as a Service NexMed has initiated discussions with potential partners regarding the application of its NexACT technology to drugs that will soon be going off-patent to help create a second-generation drug that has patent protection through the mechanism of delivery. The NexACT platform technology has demonstrated the potential to improve the topical absorption of active therapeutic ingredients and/or to develop new patient-friendlier routes of administration. Incorporating older drugs with the NexACT proprietary delivery system can create new products that not only provide patients with added therapeutic benefits, but can also extend the product life for up to an additional 20 years. As such, the Company intends to aggressively pursue these types of potential partnering arrangements going forward
NexACT technology, New Applications In addition to developing innovative topical treatments, NexMed’s new scientific team is evaluating the ability of the NexACT technology to deliver biologics, such as humanized or fully human antibodies, via transdermal application. The delivery of such biologics through the skin represents a novel approach to delivering antibodies to specific areas of the body with limited systemic exposure – potentially reducing side effects and toxicity. We are also evaluating the ability of the NexACT technology to deliver drugs orally, including various first-line oral chemotherapeutics, which currently have poor bioavailability and thus require high doses and result in certain toxic side effects
NASDAQ Listing On January 4, 2010, NexMed received an expected notice of non-compliance from The NASDAQ Stock Market LLC based upon its failure to solicit proxies and hold an annual meeting for fiscal 2008 by December 31, 2009, as required by NASDAQ Listing Rules 5620(a) and 5620(b), which could serve as an additional basis for the delisting of the Company’s securities from The NASDAQ Capital Market. NexMed had discussed this matter with the NASDAQ Listing Qualifications Panel (the “Panel”) at the hearing on November 12, 2009, and explained that it planned to postpone the 2008 annual meeting due to the ongoing acquisition of Bio-Quant and would not be able to incorporate all of the relevant acquisition related materials in the meeting proxy in a timely manner
As NexMed previously announced on December 18, 2009, the Panel granted its request to remain listed on The NASDAQ Capital Market, subject to the condition that it evidence stockholders’ equity of at least $2.5 million or a market value of listed securities of at least $35 million on or before March 31, 2010. The determination followed the hearing before the Panel on November 12, 2009, at which time NexMed presented its plan to evidence compliance with all requirements for continued listing on The NASDAQ Capital Market, including the proxy solicitation/annual meeting and bid price requirements (notwithstanding the fact that NexMed was not yet deficient with respect to those standards)
As provided by NASDAQ’s most recent notice, NexMed plans to timely make a formal written submission to the Panel presenting its plan to evidence compliance with the proxy solicitation and annual meeting requirements. While it intends to file a proxy statement for a special meeting of shareholders to be held within the next sixty days to consider amending its Articles of Incorporation to authorize more common stock for issuance, that meeting may not be conducted as an annual meeting since the proxy statement will not incorporate audited financial statements for the fiscal year ended December 31, 2009. As a result, in order to satisfy NASDAQ’s annual meeting requirement, NexMed plans to file a proxy statement for a joint 2008/2009 annual meeting promptly following the filing of its Annual Report on Form 10-K for fiscal 2009 in March 2010. Accordingly, the Company is asking the Panel to modify its previously issued decision in accordance with the Company’s revised plan of compliance. However, there can be no assurance that the Panel will grant the Company’s request
Also as previously announced, NexMed remains subject to a grace period through January 25, 2010 to evidence compliance with the $1.00 bid price requirement for continued listing on NASDAQ. In the event NexMed does not evidence compliance with the bid price requirement by that date, NexMed expects to receive an additional formal notice of non-compliance and to be afforded an opportunity to request an exception from the Panel to evidence compliance with the minimum bid price requirement. In that regard, NexMed will implement a reverse stock split, if necessary, to evidence compliance with NASDAQ’s minimum bid price requirement, which action may be taken at any time at the discretion of the NexMed Board of Directors
Corporate Integration Subsequent to the December 17, 2009 announcement of the lease of its manufacturing building in New Jersey, NexMed has completed the relocation of its headquarters to 6330 Nancy Ridge Drive, San Diego, CA 92121. NexMed now has 34 full time employees, of whom eight employees hold either Ph.D or MD degrees. NexMed will include the pro forma financial statements for the combined entity in an amendment to its December 17, 2009 Current Report on Form 8-K, to be filed on or before February 26, 2010
About NexMed NexMed, due to its recent acquisition of Bio-Quant, is the largest specialty contract research organization (“CRO”) based in San Diego, CA and is one of the industry’s most experienced CROs for in vitro and in vivo pharmacology services and research models. NexMed has a proprietary product pipeline based on its NexACT drug delivery technology, including a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information, go to www.nexmed.com and www.bio-quant.com
Forward-Looking Statement Safe Harbor Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company. For example, and without limitation, there can be no assurance that the Company will receive favorable approvability decisions from Health Canada or the FDA within the anticipated time frames or at all, the Company’s research and development activities will yield the desired results, the Company will be able to achieve or will continue to pursue its product development goals, the Company will be able to execute on its partnering strategies, the Company will be able to satisfy NASDAQ continued listing standards, and that the Company will be able to integrate its business following the Bio-Quant acquisition in a successful manner
...grabbed some (on the way to $1.00 ??!)
...grabbed some EEE
07.01.2010 13:16
http://www.finanznachrichten.de/nachrichten-2010-01/15840116-evergreen-energy-signs-a-term-sheet-to-spin-off-k-fuel-technology-to-the-investment-arm-of-a-major-chinese-conglomerate-its-affiliates-004.htm
Evergreen Energy Signs a Term Sheet to Spin-off K-Fuel Technology to the Investment Arm of a Major Chinese Conglomerate & its Affiliates
The Deal Builds on a Letter of Intent with a Major Integrated Utility and Chemical Manufacturer to Build a K-Fuel Plant in Inner Mongolia
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45101357
ADVENTRX Pharmaceuticals to Present at the OneMedForum Finance Conference on January 13
Date : 01/06/2010 @ 8:00AM
Source : PR Newswire
Stock : (ANX)
Quote : 0.29 0.0 (0.00%) @ 8:11AM
ADVENTRX Pharmaceuticals to Present at the OneMedForum Finance Conference on January 13
SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal Executive Officer, Brian M. Culley, will present at the OneMedForum Finance Conference on Wednesday, January 13, 2010, at 4:30 p.m. Pacific time. The conference will be held at the Sir Francis Drake Hotel in San Francisco
Interested parties can access a live audio webcast on the ADVENTRX Pharmaceuticals Web site at http://www.adventrx.com/. An archived presentation will be available on the Web site for 30 days
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's Web site at http://www.adventrx.com/.
DATASOURCE: ADVENTRX Pharmaceuticals, Inc
CONTACT: Brian Culley, Principal Executive Officer of ADVENTRX
Pharmaceuticals, +1-858-552-0866, or Investors, Don Markley of
Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, , for
ADVENTRX Pharmaceuticals, Inc
Web Site: http://www.adventrx.com/
Technical Trading Overview for Adventrx Pharmaceuticals Inc. (ANX)
Submitted by BeaconEquity.com
Friday, 8 January 2010
http://www.beaconequity.com/technical-trading-overview-for-adventrx-pharmaceuticals-inc-anx-2/
Technical Trading Overview for Adventrx Pharmaceuticals Inc. (ANX)
Submitted by BeaconEquity.com
Friday, 8 January 2010
http://www.beaconequity.com/technical-trading-overview-for-adventrx-pharmaceuticals-inc-anx-2/
Market Watch for Adventrx Pharmaceuticals Inc. Issued by Beacon Equity
ADVENTRX Pharmaceuticals Inc.
ANX | 1/8/2010 6:51:30 AM
http://www.stockhouse.com/News/USReleasesDetail.aspx?n=7587667
DALLAS, Jan 8, 2010 (GlobeNewswire via COMTEX News Network) --
BeaconEquity.com announces an investment report featuring biotechnology company Adventrx Pharmaceuticals Inc. (AMEX:ANX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/ANX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Adventrx Pharmaceuticals Inc. (ANX) engages in the in-licensing, development and commercialization of cancer-related proprietary drug therapies. The Company seeks to improve upon existing treatments of cancer.
In the report, the analyst notes:
"According to the Cancer Market Outlook report published by Business Insights, the market for cancer therapeutic drugs is expected to reach $40.9 billion by 2012. If approved by the U.S. Food and Drug Administration (FDA), the market for the Company's drug candidates, has a potential to reach more than $1.0 billion at market saturation.
"The Company's strategy is to take advantage of an effective lifecycle-management technique of reformulating existing successfully marketed drug therapies. Of the top 50 pharmaceutical companies, more than 40% of all drug therapies produced have been reformulated to extend the life of existing marketed drugs between the years 2002 and 2005. Patent expirations and competition are threats to all pharmaceutical companies. Modified and improved existing products have become an important technique as a method of improving revenue stream for longer time periods."
To read the entire report visit: http://www.beaconequity.com/i/ANX
See what investors are saying about these stocks at penny stock forum.
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Beacon Equity
CONTACT: Beacon Equity Research Jeff Bishop (469)-252-3505 press@beaconequity.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
Market Watch for Adventrx Pharmaceuticals Inc. Issued by Beacon Equity
ADVENTRX Pharmaceuticals Inc.
ANX | 1/8/2010 6:51:30 AM
http://www.stockhouse.com/News/USReleasesDetail.aspx?n=7587667
DALLAS, Jan 8, 2010 (GlobeNewswire via COMTEX News Network) --
BeaconEquity.com announces an investment report featuring biotechnology company Adventrx Pharmaceuticals Inc. (AMEX:ANX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/ANX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Adventrx Pharmaceuticals Inc. (ANX) engages in the in-licensing, development and commercialization of cancer-related proprietary drug therapies. The Company seeks to improve upon existing treatments of cancer.
In the report, the analyst notes:
"According to the Cancer Market Outlook report published by Business Insights, the market for cancer therapeutic drugs is expected to reach $40.9 billion by 2012. If approved by the U.S. Food and Drug Administration (FDA), the market for the Company's drug candidates, has a potential to reach more than $1.0 billion at market saturation.
"The Company's strategy is to take advantage of an effective lifecycle-management technique of reformulating existing successfully marketed drug therapies. Of the top 50 pharmaceutical companies, more than 40% of all drug therapies produced have been reformulated to extend the life of existing marketed drugs between the years 2002 and 2005. Patent expirations and competition are threats to all pharmaceutical companies. Modified and improved existing products have become an important technique as a method of improving revenue stream for longer time periods."
To read the entire report visit: http://www.beaconequity.com/i/ANX
See what investors are saying about these stocks at penny stock forum.
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Beacon Equity
CONTACT: Beacon Equity Research Jeff Bishop (469)-252-3505 press@beaconequity.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
...still holding 1500 KERX @ 0,30€ and 450 @ 2,00€ with different accounts
(maybe will sold my 450 KERX @ 4,00€ !)
Cyclacel says drug found effective against lung cancer, shrs up
08.01.2010 00:14
http://www.finanznachrichten.de/nachrichten-2010-01/15845467-cyclacel-says-drug-found-effective-against-lung-cancer-shrs-up-020.htm
Cyclacel says drug found effective against lung cancer, shrs up
Jan 7 (Reuters) - Biopharmaceutical company Cyclacel Pharmaceuticals said two peer-reviewed journal articles found its drug candidate, seliciclib, effective against lung cancer.
Shares of Cyclacel were up 19 percent at $3.17 in aftermarket trade. They closed up 152 percent at $2.67 Thursday on Nasdaq.
One of the articles said seliciclib was found to be effective in killing lung cancer cells through a novel apoptotic mechanism or induction of cancer cell suicide.
Nearly all lung cancer cell lines against which the drug was most effective had Ras-activating mutations.
Ras is a family of mutations which make lung cancer cells highly resistant to approved drugs, the company said.
'If seliciclib is found to be effective in patients with Ras-mutant non-small cell lung cancer (NSCLC) it could address an area of high unmet medical need,' Cyclacel's Chief Scientist David Glover said in the statement.
The drug seliciclib is currently in mid-stage trials for the treatment of NSCLC.
(Reporting by Anuradha Ramanathan in Bangalore; Editing by Aradhana Aravindan) Keywords: CYCLACEL/
(anuradha.ramanathan@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800: Reuters Messaging: anuradha.ramanathan.reuters.com@reuters.net)
COPYRIGHT
Copyright Thomson Reuters 2010. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
...still in - NO
20 GOOD things about ANX
Posted by: vinnyprospero Date: Thursday, January 07, 2010 9:33:33 PM
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45253964
20 GOOD things about ANX:
FROM SOMEONE I TRUST
1) No debt
2) NOT a high float
3) GOOD pre-clinical test results with their drug.
4) NDA then FDA
4) Buyout, Partnership or
Merger, all possible in the future.
5) Insiders, Mutual Funds, Institutions and Carl Icahn all hold MILLIONS of ANX shares.
6) Volume has been increasing and that means more interest.
7) VERY high NEW potential revenue streams in the future with both of their CANCER drugs.
8) Cancer drug stock means this stock has great upside share price increase potential providing their drug is safe and effective as it has already been shown to be. They have 2 drugs.
9) Company NOW is in a good cash position.
10) The ANX Share price is very low now which just means that this stock (ANX) can go to 2-5
dollars
just like other drug stocks did this year did all from a low of 15 cents or less, CTIC, CVM, SNSS, TTNP.pk, INO, and several others so ANX will also go above 2 dollars and soon
just like other drug stocks
this year that were LESS than 15 cents this year and then went to over 2 dollars this year.
11) Very bullish signals now in volume, price, accumulation and momentum on every chart. Very strong support at the current share price.
12) $1.20 price target from Yahoo Finance and that could be too low.
13) Seeking Alpha a very well respected and excellent source now says that ANX is VERY undervalued. Check out the great information (analysis) that Seeking Alpha wrote twice about ANX in the last few days.
14) FDA approval will be in less than one year and Korean company also ready to market this cancer drug.
15) Stock symbol KERX & OPXA were both
9 cents this year and
recently went over 3 dollars, KERX is a cancer stock like ANX is.
16) ANX has been on the CNBC ticker several times the last few days. That shows that this stock is as legitimate as any other great stock but ANX has even more potential than others.
17) Bashers posting over here on this message board is a very positive thing. Have you all noticed the increase in the number of basher postings here in the last few days? If the past is any guage, the more bashers you see with ANY stock the better the chances of that particular stock going higher. Bashers do not waste their time bashing a "bad" stock. Bashers have an agenda and their agenda is to keep the share price low of any stock they bash through lies, tricks and deception and they do that for a variety of reasons in wanting to keep the share price low of any stock that they are bashing. They want to create fear, doubt and panic to try to get you to sell your shares.
As the share price goes higher they end up very frustrated so too bad for them.
18) Street.com & BiomedReports.com and other blogs are now writing about ANX so more attention means more interest and more buying.
19) Important conference in a few days will be good for ANX in getting more exposure.
20) Financing now is important and very positive as somebody invests several million dollars into this company because they believe in it and the NEW financing will help ANX market their drug so what is wrong with that?
By the way, making people aware of this information should NOT be considered "pumping" just because it is very positive. If you have anything to dispute any of the above information then you should do so. Just be specific and just be factual with your comments instead of posting absurd, idiotic, and negative nonsense to fit your own bashing agenda for this stock, ANX.
FACTS are more important than OPINIONS!
WaMu Equity Meeting Set for Monday
01/07/10 - 04:37 PM EST
http://www.thestreet.com/story/10657890/1/wamu-equity-meeting-set-for-monday.html?puc=_tscrss
holding now...
~9K shares ANX
~3K shares CVM
~2K shares KERX
and other Bio's...
ADVENTRX Pharmaceuticals Announces Closing of Financing
Date : 01/07/2010 @ 4:18PM
Source : PR Newswire
Stock : (ANX)
http://ih.advfn.com/p.php?pid=nmona&article=41016392&symbol=ANX
The Hartford Appoints McGee President of The Hartford
Date : 01/07/2010 @ 4:15PM
Source : Business Wire
Stock : The Hartford Financial Services Group, Inc. (HIG)
http://ih.advfn.com/p.php?pid=nmona&cb=1262899113&article=41016313&symbol=NY^HIG
The Hartford Financial Services Group, Inc. (NYSE: HIG) today announced that its Board of Directors has appointed Liam E. McGee President of the company, in addition to his roles as Chairman and Chief Executive Officer
“In his first three months on the job, we have been impressed with Liam’s leadership of The Hartford,” said Michael G. Morris, Presiding Director of The Hartford’s Board of Directors. “The additional title of President is in recognition of his work to date and our expectations of the future he and his team are building for The Hartford. As the company enters its third century, we are confident that The Hartford is on the right track towards profitable growth and delivering value to our shareholders.”
About The Hartford
Celebrating nearly 200 years, The Hartford (NYSE: HIG) is an insurance-based financial services company that serves households, businesses and employees by helping to protect their assets and income from risks, and by managing wealth and retirement needs. A Fortune 500 company, The Hartford is recognized widely for its service expertise and as one of the world’s most ethical companies. More information on the company and its financial performance is available at www.thehartford.com
HIG-F Some of the statements in this release may be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. We caution investors that these forward-looking statements are not guarantees of future performance, and actual results may differ materially. Investors should consider the important risks and uncertainties that may cause actual results to differ. These important risks and uncertainties include those discussed in our Quarterly Reports on Form 10-Q, our 2008 Annual Report on Form 10-K and the other filings we make with the Securities and Exchange Commission. We assume no obligation to update this release, which speaks as of the date issued
ProLogis to Host Fourth Quarter/Year End 2009 Financial Results Webcast and Conference Call
Date : 01/06/2010 @ 5:15PM
Source : PR Newswire
Stock : Prologis (PLD)
http://ih.advfn.com/p.php?pid=nmona&article=40998129&symbol=PLD
DENVER, Jan. 6 /PRNewswire-FirstCall/ -- ProLogis (NYSE:PLD), a leading global provider of distribution facilities, will host its Fourth Quarter/Year End 2009 Financial Results Webcast and Conference Call with senior management to discuss quarterly results, current market conditions and future outlook on Thursday, February 11, 2010, at 10:00 a.m. Eastern Time
Earnings Release
ProLogis' fourth quarter/year end 2009 financial results will be released on Thursday, February 11, 2010, before market open and will be available on the ProLogis website, ir.prologis.com/, in the "Annual & Supplemental Reports" section
Earnings Webcast and Conference Call
Interested parties are encouraged to access the live webcast by clicking the microphone icon located near the top of the opening page on the ProLogis website at ir.prologis.com/. Interested parties can also participate via conference call by dialing (866) 305-2304 domestically or (660) 422-4873 internationally
Replay Information
A replay of the conference call will be available after 1:00 p.m. Eastern Time on Thursday, February 11, 2010. The replay will be available until midnight Eastern Time on Thursday, February 25, 2010, and can be accessed by dialing (800) 642-1687 domestically or (706) 645-9291 internationally and entering the passcode 49471953. A transcript of the call and the webcast replay will be available in the "Quarterly Results" section on the ProLogis website
About ProLogis
ProLogis is a leading global provider of distribution facilities, with more than 475 million square feet of industrial space owned and managed (44 million square meters) in markets across North America, Europe and Asia. The company leases its industrial facilities to more than 4,500 customers, including manufacturers, retailers, transportation companies, third-party logistics providers and other enterprises with large-scale distribution needs. For additional information about the company, go to http://www.prologis.com/.
DATASOURCE: ProLogis
CONTACT: Robbin Lee of ProLogis, +1-303-567-5690,
Web Site: http://www.prologis.com/